STX-005: A Next-Generation Therapy for Autoimmune Disease to Sustain Force Readiness

Autoimmune diseases pose a serious threat to the operational readiness and long-term health of Warfighters across the U.S. Air Force and DoD at large. Conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and multiple sclerosis can significantly impair a Warfighter’s ability to meet mission demands, affecting everything from combat effectiveness to deployability. Under DoD Instruction 6130.03, Warfighters diagnosed with chronic autoimmune conditions face mandatory medical discharge, as these conditions are considered incompatible with the physical and operational demands of military service.  Additionally, 6130.03 precludes individuals with these conditions from enlisting in the first place, further limiting the Air Force’s ability to recruit and retain a highly skilled and lethal force. This strict medical separation policy, while designed to maintain a combat-ready force, often results in the involuntary discharge of highly trained and experienced Warfighters, even when their conditions could be effectively managed with the right medical advancements. As a result, the Air Force loses mission-critical expertise, placing greater strain on recruitment, training, and force retention—all of which directly impact readiness and national security. A 2023 population-based study found that autoimmune disorders now affect 10% of the population, posing a growing health challenge with direct implications for military recruitment and force readiness. Additionally, the prevalence of antinuclear antibodies (ANA), a key biomarker of autoimmunity, has surged over the past 25 years, particularly among teenagers. Data from the National Health and Nutrition Examination Survey (NHANES) showed ANA prevalence rising from 11.0% to 16.1%, equating to an increase from 22.3 million to 41.5 million affected individuals in the U.S. Strand Therapeutics, a U.S.-based biotechnology company, is developing STX-005, a next-generation mRNA-based immunotherapy designed to reprogram a patient’s immune system to selectively target and eliminate disease-causing cells. By leveraging programmable mRNA technology, STX-005 offers a precise, scalable, and deployable treatment for autoimmune diseases, addressing a critical gap in military healthcare and ensuring Warfighters maintain operational readiness. STX-005 works by harnessing the natural ability of cytotoxic T-cells to destroy infected cells. Cytotoxic T-cells, also known as “killer” T-cells, identify and eliminate compromised host cells, including virus-infected cells. These T-cells rely on receptors (TCRs) to recognize specific antigens on target cells, allowing them to selectively attack and destroy harmful cells while leaving healthy ones unharmed. STX-005 harnesses cytotoxic T-cells to treat autoimmune diseases by re-directing T-cells to destroy the dysfunctional immune cells responsible for producing self-reactive (“autoreactive”) antibodies that drive autoimmune diseases.